Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Pirfenidone and Nintedanib are specific drugs used against idiopathic pulmonary fibrosis
(IPF) that showed efficacy in non-IPF fibrosing interstitial lung diseases (ILD). Both drugs …

Background Pirfenidone is a novel anti-fibrotic drug that has shown efficacy in five
randomized multicenter clinical trials enrolling patients with Idiopathic Pulmonary Fibrosis of …

The magnitude of treatment effect can be assessed by a number of methods. One method of
collectively analysing data is that used by the Cochrane Collaboration. Their systematic …

BACKGROUND: Conducting an adequately powered survival study in idiopathic pulmonary
fibrosis (IPF) is challenging due to the rare nature of the disease and the need for extended …

Rationale: In October 2014, the antifibrotic medications pirfenidone and nintedanib became
the first medications approved by the US Food and Drug Administration for use in patients …

Treatment of idiopathic pulmonary fibrosis (IPF) has been transformed in the last few years
with the development and regulatory approval of two novel antifibrotic drugs, pirfenidone …

Background Pirfenidone is currently approved in the EU for the treatment of mild to moderate
idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there …

There are errors in the ninth and tenth sentences of the Abstract. These sentences should
read: Also there was a decrease in the risk of progression (RR of PFS: 0.82 IC 0.73–0.92) …

In retrospect, 2014 will be seen as the year in which idiopathic pulmonary fibrosis (IPF)
therapies came of age. Treatment effects reported previously were inconclusive with regard …